NEWARK, Calif. and DEL MAR, Calif., June 15, 2020 /PRNewswire/ — ATUM and Phylex BioSciences have entered into a collaboration to leverage ATUM’s Leap-In Transposase® platform to develop the cell line essential to the manufacturing of Phylex’s universal SARS coronavirus vaccine candidate. The Phylex vaccine candidate aims to protect people against SARS-CoV-2 and other highly pathogenic SARS coronaviruses that may follow in the future.
The Phylex vaccine candidate antigen contains conserved epitopes close to the receptor-binding domain of the SARS coronavirus S-protein. A large number of copies of this antigen are displayed on a virus-like particle (VLP). This VLP, expressed by a single gene, self-assembles after being secreted by the cell line that is being developed by ATUM.
“We are extremely pleased to announce this collaboration with ATUM which we believe will accelerate the development of our universal SARS coronavirus vaccine candidate,” said Pascal Brandys, co-founder and CEO of Phylex BioSciences. “ATUM’s leap-in transposases and synthetic transposons enable a robust cell line development program for our universal SARS coronavirus vaccine. With this collaboration we will be able to start development in parallel with immunogenicity studies expediting our timeline to initiate clinical trials. Our objective is to offer not only a universal vaccine candidate against the SARS coronavirus by this fall, but also a clear and accelerated path to GMP-compliant manufacturing and clinical development.”
“A universal coronavirus vaccine has the potential to provide an important new resource for fighting pandemic outbreaks now and in the future and we are proud to collaborate with Phylex to deliver on this vision,” said Oren Beske, PhD, senior vice president of corporate strategy at ATUM. “ATUM’s Leap-In platform is a rapid and robust cell line development platform that derisks the transfer, process development, scale-up and manufacturing of vaccines.”
About Phylex BioSciences
Founded at the beginning of the SARS-CoV-2 pandemic by genomics pioneer Pascal Brandys and coronavirus specialist Jens Herold, Phylex BioSciences is the first company to pursue the development of a universal vaccine against the SARS coronavirus. The result of antigen engineering with conserved epitopes combined with latest generation VLP technology, the vaccine is intended to protect not only against SARS-CoV-2 but also against other virulent strains of the SARS coronavirus to come. For more information please visit: www.phylexbio.com
About ATUM
ATUM offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and cellular engineering and production. The company exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster. For more information please visit: www.atum.bioSOURCE Phylex BioSciences
For further information from ATUM please contact:
Ian Taylor, CBO
T: +44 (0)1202 051813
ATUM
Claes Gustafsson, CCO
T: 1 (650) 853 8347